Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 21, 2014Clinical Cancer Research

Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAbdulmohsen AlhejailyKing Fahd Medical CityADAndrew G. DayKingston Health Sciences CentreHFHarriet FeilotterUniversity Health Network

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Alhejaily et al. (2014) studied this question.

synapsesocial.com/papers/6a852b09fa721725e8928ad9https://doi.org/10.1158/1078-0432.ccr-13-2175
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias2008 · 69 citations
  2. 2Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma1995 · 64 citations
  3. 3Comprehensive Analysis of Copy Number and Allele Status Identifies Multiple Chromosome Defects Underlying Follicular Lymphoma Pathogenesis2007 · 112 citations
  4. 4Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas2008 · 33 citations
  5. 5pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene2007 · 316 citations